Roivant Sciences Ltd. Common Shares (ROIV) Stock Analysis
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy19 analystsStrengths
- ✓Altman Z 58.9 — safe-zone balance sheet
Risks
- ⚠Beneish M 2.02 — earnings-manipulation flag
- ⚠Negative FCF margin (-2.0%) — burning cash
- ⚠SBC 2648.3% of revenue — real dilution cost
- ⚠3 loss-making years in recent history
- ⚠Interest coverage -72.8× — thin debt cushion
What's happening with ROIV
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; growth, profitability, earnings quality and valuation lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.0%)0/25
- P/S (1942.9x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (-27.5%)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-19.0%)0/25
- Net margin (-6079.9%)0/25
- Operating margin (-9130.5%)0/25
- Financial Health75/100 · Strong
- Altman Z (58.94)25/25
- Current ratio (30.66)25/25
- Interest coverage (-72.8x)0/25
- Net cash / debt (Net cash)25/25
- Quality5/100 · Weak
- Piotroski F (3/9)5/25
- Beneish M (2.02)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 5264.8%)0/25
About Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Show more
It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Headquarters: LONDON · Employees: 721 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellTax withholding · filed 2026-09-22-2129 sh2026-09-20
- SellTax withholding · filed 2026-09-22-3880 sh2026-09-20
- BuyGrant / award · filed 2026-09-18+10.5K sh2026-09-16
- BuyGrant / award · filed 2026-09-18+5.1K sh2026-09-16
- BuyGrant / award · filed 2026-09-18+10.5K sh2026-09-16
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.0%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -33.9%–-2.7% · 99th pct
P/S (TTM)1942.90xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 37.1x–2155.1x · 99th pct
EV/EBITDA5.7xA
Grade A: CheapEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3299.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.06xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-19.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-5.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-6079.9%D
Grade D: LowNet Income / Revenue
Operating Margin-9130.5%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin84.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-200.0%D
Grade D: LowFCF / Revenue
True FCF Margin-8409.8%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
75B+Altman Z-Score58.94A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio30.66xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio18.37xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-72.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
0ERevenue CAGR-27.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue2648.3%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
3/3 Loss Years5EPiotroski F-Score3/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score2.02D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability5264.8%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue58.3%D
Grade D: HeavyTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.00xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$5.96
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.28
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$4.53B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$4.27B
Shareholders' equity (book value)
Asset / Liability20.81xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$25.86B
Current Market Capitalization
Beta1.23C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Dec 2025 · Ratio snapshot Sep 26, 2026
Key Insights: Roivant Sciences Ltd. Common Shares (ROIV)
Roivant Sciences Ltd. Common Shares meets only 3 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 58.94 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of 2.02 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Revenue has been contracting (CAGR ≈ -28%), which weighs on the growth outlook. Free-cash-flow margin is negative (-200%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -72.8× leaves little room for earnings shocks.
- Roivant Sciences Ltd. Common Shares posted a net loss in 3 of 3 available completed fiscal years (2022–2024).
- At a valuation score of 20/100, ROIV trades at a premium to its historical multiples.
See how ROIV ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for ROIV in the last 30 days.
See ROIV move history →Frequently Asked Questions about ROIV
Is ROIV stock a buy right now?
PreMarketPrice's quantitative model rates Roivant Sciences Ltd. Common Shares's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ROIV stock overvalued?
Roivant Sciences Ltd. Common Shares trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Roivant Sciences Ltd. Common Shares report earnings?
No confirmed earnings date is currently scheduled for ROIV. The Earnings section lists recent reports and updates as dates are announced.
What sector does Roivant Sciences Ltd. Common Shares operate in?
Roivant Sciences Ltd. Common Shares operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Roivant Sciences Ltd. Common Shares do?
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
About Roivant Sciences Ltd. Common Shares (ROIV) Stock
Roivant Sciences Ltd. Common Shares (ROIV) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. Real-time pricing data for Roivant Sciences Ltd. Common Shares is available on this page with a market capitalization of $25.9 billion. The financial health score for ROIV is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ROIV stock.
ROIV Stock Analysis & Key Metrics
On PreMarketPrice, you can track Roivant Sciences Ltd. Common Shares (ROIV) across multiple dimensions:
- Pre-market price & movement: Real-time ROIV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ROIV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Roivant Sciences Ltd. Common Shares across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ROIV.
- Sector peers: Compare ROIV against 10 other healthcare stocks on key financial metrics.
Is ROIV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Roivant Sciences Ltd. Common Shares (ROIV) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Roivant Sciences Ltd. Common Shares (ROIV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.